MBX Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 55.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.69B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo...